Evidence map›Paper›PMID 36291923›Full record

ReviewCancers2022

The Role of m

Yuekao Li, Chaoxu Niu, Na Wang, Xi Huang, Shiru Cao, Saijin Cui, Tianyu Chen, Xiangran Huo, Rongmiao Zhou

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Clinical significance of RNA methylation in hepatocellular carcinoma.Cell communication and signaling : CCS · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yuekao LiDepartment of Computed Tomography, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Chaoxu NiuDepartment of Surgery, Shijiazhuang Ping'an Hospital, Shijiazhuang 050021, China.
Na WangHebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Xi HuangHebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Shiru CaoHebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Saijin CuiHebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Tianyu ChenHebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Xiangran HuoHebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Rongmiao ZhouHebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Fourth Hospital of Hebei Medical University · CNHebei Medical University · CNFirst Hospital of Shijiazhuang · CN

Funding

Hebei Province Medical Science Research Key Project [No. 20180533]
6 · The paper itself

Abstract

N

Indexed as

esophageal cancerm6A modificationm6A regulatorsoccurrenceprognosisprogressiontreatment

Identifiers

PMID36291923
PMCPMC9600289
OpenAlexW4306920811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.